<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735758</url>
  </required_header>
  <id_info>
    <org_study_id>PazoQoL</org_study_id>
    <nct_id>NCT03735758</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib</brief_title>
  <acronym>PazoQoL</acronym>
  <official_title>Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib - a Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Finding the balance between toxicity and benefit should be the major goal when negotiating&#xD;
      about the therapeutic regimen. This becomes nowadays even more important, since there are&#xD;
      emerging options in the field of sarcoma therapy. Especially in the palliative treatment of&#xD;
      sarcoma patients, knowing that na single drug can provide an overall survival benefit,&#xD;
      physicians have to incorporate the patient's preferences and goals in life when consulting&#xD;
      them.&#xD;
&#xD;
      The study will allow patients with several types of soff tissue sarcoma to be included. After&#xD;
      progression under current therapy, the patient will be randomized in a 1:1 fashion and&#xD;
      allocated to either pazopanib or investigator's choice. Quality of life (QoL) and other&#xD;
      secondary outcome measures will be recorded continuously. The aim of the study is to assess&#xD;
      patient reported outcomes (PROs), which should be the primary aim when treating these&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives&#xD;
&#xD;
      • Assess the overall quality of life (QoL) under treatment with pazopanib or&#xD;
      physician-preferred chemotherapy after 9 weeks&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Assess the overall QoL under treatment with pazopanib compared with the physician's&#xD;
           preference of chemotherapy three times in Cycle 1 and Cycle 3&#xD;
&#xD;
        -  intergroup evaluation of pain&#xD;
&#xD;
             -  intergroup evaluation of fatigue and its different categories (physical, mental,&#xD;
                cognitive, emotional)&#xD;
&#xD;
             -  intergroup evaluation of anorexia/cachexia&#xD;
&#xD;
             -  intergroup evaluation of satisfaction with care&#xD;
&#xD;
             -  Evaluation of the association of QoL with criteria of response&#xD;
&#xD;
             -  Evaluation of the QoL of all patients during follow up (FU) intergroup evaluation&#xD;
                of treatment effects on survival&#xD;
&#xD;
        -  Evaluation of the prediction of severe early toxicity in elderly patients receiving&#xD;
           palliative therapy&#xD;
&#xD;
        -  Safety and efficacy of the different treatment regimens&#xD;
&#xD;
      Exploratory Endpoints:&#xD;
&#xD;
        -  QLQ-C30 sum score AUC (Area Under the Curve)&#xD;
&#xD;
        -  Questionnaire Completion Times of QLQ-C30&#xD;
&#xD;
        -  Questionnaire Completion of Time Tradeoff&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    problems with recruiting&#xD;
  </why_stopped>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicentric, controlled, randomized, open Label, parallel-group, prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The sum scores of the overall Quality of live (Qol) recorded with the questionaire &quot;QLQ-C30&quot; in patients with pazopanib versus chemotherapy treatment.</measure>
    <time_frame>9 weeks</time_frame>
    <description>The 30 items of the QLQ-C30 questionaire distribute in diverse subscales (for example: cognitive function, pain and emotional function). The sum score of QLQ-C30 is generated by average of the normative values of all subscales. The higher the sum score the higher the Quality of live (Qol).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Soft Tissue Sarcoma Adult</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib; 800 mg; daily; oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Guideline-conform chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pazopanib or guideline conform chemotherapy</intervention_name>
    <description>Pazopanib (800mg/each day) or guideline conform chemotherapy</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The informed consent form must be signed before any study specific tests or procedures&#xD;
             are done&#xD;
&#xD;
          -  Male or female patients aged 18 years and older at the first screening visit&#xD;
&#xD;
          -  Histologically confirmed diagnosis of advanced or metastatic non adipocyte soft tissue&#xD;
             sarcoma (STS)&#xD;
&#xD;
          -  Suitable for treatment with pazopanib in an in-label prescription&#xD;
&#xD;
          -  Patients with a life expectancy of at least 6 months&#xD;
&#xD;
          -  Eastern Co-operative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Adequate organ function as given in Table 1&#xD;
&#xD;
          -  For patients with previous anthracycline therapy a normal heart function needs to be&#xD;
             documented with an left ventricular ejection fraction (LVEF) of minimal 50%&#xD;
             (echocardiogram)&#xD;
&#xD;
          -  Patients must be willing and able to fill in the Quality of live (QoL) questionnaires&#xD;
             using a tablet PC&#xD;
&#xD;
          -  Ability to understand and follow study-related instructions&#xD;
&#xD;
          -  Confirmation of the subject's health insurance coverage prior to the first visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pretreatment with pazopanib&#xD;
&#xD;
          -  Contraindications according to the local Summary of product characteristics ( SmPC) of&#xD;
             Votrient®&#xD;
&#xD;
          -  Patients having to following STS specific tumors&#xD;
&#xD;
               -  adipocyte sarcoma including all subtypes,&#xD;
&#xD;
               -  all rhabdomyosarcoma, which are not alveolar or pleomorph&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing-tumors, i.e. primitive neuroectodermal tumors (PNET), gastrointestinal&#xD;
                  stromal tumor (GIST)&#xD;
&#xD;
               -  Dermatofibrosarcoma protuberans&#xD;
&#xD;
               -  inflammatory myofibroblastic sarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
               -  Mixed mesenchymal and epidermal tumors of the uterus Other malignant underlying&#xD;
                  diseases with the exception of the following:&#xD;
&#xD;
               -  Free of disease for at least 3 years&#xD;
&#xD;
               -  Completely resected, non-melanoma skin cancer&#xD;
&#xD;
               -  Successfully treated carcinoma in situ&#xD;
&#xD;
               -  Patients with metastases of the central nervous system (CNS) at screening, which&#xD;
                  are asymptomatic AND do not require treatment with steroids or enzyme-inducing&#xD;
                  anticonvulsant drugs&#xD;
&#xD;
               -  Patients with metastases of the CNS, which are already treated (operation and/or&#xD;
                  radiotherapy, radiosurgery or gamma-knife)&#xD;
&#xD;
          -  Major surgery or trauma within 28 days before the first dose of study medication and /&#xD;
             or presence of a non-healing wound, fracture, or ulcer&#xD;
&#xD;
          -  Clinical indications of an active bleeding or a bleeding diathesis&#xD;
&#xD;
          -  Known endobronchial lesions or lesions that infiltrate the large pulmonary artery&#xD;
&#xD;
          -  Hemoptysis of&gt; 2.5 mL within 8 weeks before the first dose of study drug&#xD;
&#xD;
          -  Existing uncontrolled infection&#xD;
&#xD;
          -  Heart rate-corrected QT-time according to the Fridericia's-formula (QTcF) 450 ms in&#xD;
             males and 460 ms in females&#xD;
&#xD;
          -  History of one or more of the following cardiovascular diseases within the last 6&#xD;
             months:&#xD;
&#xD;
               -  Cardiac angioplasty or coronary stent&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Coronary artery bypass surgery&#xD;
&#xD;
               -  Symptomatic peripheral arterial disease&#xD;
&#xD;
          -  Cardiac insufficiency New York Heart Association (NYHA) functional dass III or IV&#xD;
&#xD;
          -  Poorly controlled hypertension defined as systolic blood pressure 140 mmHg or&#xD;
             diastolic blood pressure 90 mmHg&#xD;
&#xD;
          -  History of cerebrovascular disease, including transient ischemic attacks (TIA),&#xD;
             pulmonary embolism or untreated deep vein thrombosis within 6 months prior to study&#xD;
             entry. Patients with deep vein thrombosis who have received therapeutic&#xD;
             anticoagulation for a minimum of 6 weeks might be included in the study.&#xD;
&#xD;
          -  Clinically significant gastrointestinal changes that increase the risk of&#xD;
             gastrointestinal bleeding&#xD;
&#xD;
          -  Clinically significant gastrointestinal changes that may affect the absorption of the&#xD;
             study drugs&#xD;
&#xD;
          -  Treatment with any of the following anti-neoplastic therapies:&#xD;
&#xD;
               -  Irradiation or Tumor embolization within 14 days prior to the first dose of study&#xD;
                  drug&#xD;
&#xD;
               -  Chemotherapy, immunotherapy, biological therapy, study medication or hormonal&#xD;
                  therapy within 14 days or 5 half lives of substance (whichever is langer) prior&#xD;
                  to the first dose of study drug&#xD;
&#xD;
          -  If the discontinuation of prohibited medication (see Section 6.9) at least 14 days or&#xD;
             5 half-lives of substance (whichever is langer) prior to the first dose of pazopanib&#xD;
             is medically not acceptable or refused by the patient&#xD;
&#xD;
          -  A history of hypersensitivity to any of the study drugs or their ingredients or to&#xD;
             drugs with similar chemical structure&#xD;
&#xD;
          -  Addiction or other diseases that preclude the patient from appropriately assessing the&#xD;
             nature and scope as well as possible consequences of the clinical trial&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of childbearing potential unless women who meet the following criteria:&#xD;
&#xD;
               -  Post-menopausal (12 months natural amenorrhea without any application of a&#xD;
                  hormonal contraceptive or hormonal substitution therapy))&#xD;
&#xD;
               -  Postoperatively (6 weeks after bilateral ovariectomy with or without&#xD;
                  hysterectomy)&#xD;
&#xD;
               -  Regular and correct use of a contraceptive method with error rate &lt;1% per year&#xD;
                  such as implants, depot injections, oral contraceptives or intrauterine devices&#xD;
                  during treatment and up 6 months after end of treatment&#xD;
&#xD;
               -  Sexual abstinence&#xD;
&#xD;
               -  Vasectomy of the partner&#xD;
&#xD;
          -  Men of sexual activity with women of childbearing potential who are not willing to use&#xD;
             an effective barrier method of contraception during and up to 6 months after the end&#xD;
             of therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schuler, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>HELIOS Klinikum Emil von Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarkomzentrum Berlin-Brandenburg</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der Paracelsus Privatuniversität Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in-label prescription</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>pazopanib</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

